New data suggest that Lecanemab , a experimental monoclonal antibody , could lessen the development of mild cognitive decline. This treatment focuses on clearing beta-amyloid in the mind, a https://berthagvat616588.activoblog.com/51547182/donanemab-an-emerging-new-dementia-approach